Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation’ Category

World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on January 18, 2021| Leave a Comment »


World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Reporter: Aviva Lev-Ari, PhD, RN

 

Davos Agenda

https://www.weforum.org/events/the-davos-agenda-2021

 

Adrian Monck, Managing Director, Public Engagement, public.affairs@weforum.org

日本語 | 中文 | عربي

World Leaders to Meet During Davos Agenda in a Crucial Year to Rebuild Trust

  • The Davos Agenda 2021 will convene under the theme: A Crucial Year to Rebuild Trust
  • The World Economic Forum will gather the world’s foremost leaders to address the economic, environmental, social and technological challenges following the COVID-19 pandemic 
  • More than 1,500 business, government and civil society leaders from over 70 countries will set the agenda for a critical year ahead and discuss how to catalyse impact in the rapidly advancing Fourth Industrial Revolution
  • The conclusions from the Davos Agenda week will feed into task forces working on global issues for the upcoming Special Annual Meeting in Singapore
  • For more information, please visit http://www.weforum.org; share on social media using the hashtag #DavosAgenda

Geneva, Switzerland, 18 January 2021 – The World Economic Forum Davos Agenda, taking place virtually on 25-29 January, will bring together the foremost leaders of the world to address the new global situation. Heads of state and government, chief executives and leaders from civil society will convene under the theme: A Crucial Year to Rebuild Trust.

The meeting will focus on creating impact, rebuilding trust and shaping the policies and partnerships needed in 2021.

“In the context of the COVID-19 pandemic, the need to reset priorities and the urgency to reform systems have been growing stronger around the world,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. “Rebuilding trust and increasing global cooperation are crucial to fostering innovative and bold solutions to stem the pandemic and drive a robust recovery. This unique meeting will be an opportunity for leaders to outline their vision and address the most important issues of our time, such as the need to accelerate job creation and to protect the environment.”

The COVID-19 pandemic has demonstrated that no institution or individual alone can address the economic, environmental, social and technological challenges of our complex, interdependent world. The pandemic has accelerated systemic changes that were apparent before its inception. The fault lines that emerged in 2020 now appear as critical crossroads in 2021. The Davos Agenda will help leaders choose innovative and bold solutions to stem the pandemic and drive a robust recovery over the next year.

The five programme themes are:

  1. Designing cohesive, sustainable, resilient economic systems (25 January)
  2. Driving responsible industry transformation and growth (26 January)
  3. Enhancing stewardship of the global commons (27 January)
  4. Harnessing the technologies of the Fourth Industrial Revolution (28 January)
  5. Advancing global and regional cooperation (29 January)

Special addresses from G20 heads of state and government and international organizations will provide crucial insights into a range of important issues in the year ahead. Participants will hear first-hand how these public figures will demonstrate leadership and drive action in areas such as the environment, jobs, and advances in innovation brought by the Fourth Industrial Revolution.

Heads of state and government include:

Xi Jinping, President of the People’s Republic of China; Narendra Modi, Prime Minister of India; Yoshihide Suga, Prime Minister of Japan; Emmanuel Macron, President of France; Angela Merkel, Federal Chancellor of Germany; Ursula von der Leyen, President of the European Commission; Giuseppe Conte, Prime Minister of Italy; Moon Jae-in, President of the Republic of Korea; Alberto Fernández, President of Argentina; Cyril Ramaphosa, President of South Africa; Pedro Sánchez, Prime Minister of Spain; Guy Parmelin, President of the Swiss Confederation and Federal Councillor for Economic Affairs, Education and Research; Ivan Duque, President of Colombia; Carlos Alvarado Quesada, President of Costa Rica; Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana; Kyriakos Mitsotakis, Prime Minister of Greece; Benjamin Netanyahu, Prime Minister of Israel; Abdullah II ibn Al Hussein, King of the Hashemite Kingdom of Jordan; Paul Kagame, President of Rwanda; Lee Hsien Loong, Prime Minister of Singapore, the host of the World Economic Forum Special Annual Meeting 2021.

Other world leaders are expected to confirm.

Leaders from international organizations, government agencies and central banks include:

António Guterres, Secretary-General, United Nations (UN); Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO); Kristalina Georgieva, Managing Director, International Monetary Fund (IMF); Amina Mohammed, Deputy Secretary-General, United Nations (UN); Achim Steiner, Administrator, United Nations Development Programme (UNDP); Phumzile Mlambo-Ngcuka, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN); Dongyu Qu, Director-General, Food and Agriculture Organization of the United Nations (FAO); Inger Andersen, Executive Director, United Nations Environment Programme (UNEP); Henrietta Fore, Executive Director, United Nations Children’s Fund (UNICEF); David Beasley, Executive Director, United Nations World Food Programme (WFP); Fang Liu, Secretary-General, International Civil Aviation Organization (ICAO); Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Angel Gurría, Secretary-General, Organisation for Economic Co-operation and Development (OECD); Mauricio Claver-Carone, President, Inter-American Development Bank (IDB); Guy Ryder, Director-General, International Labour Organization (ILO); Jürgen Stock, Secretary-General, International Criminal Police Organization (INTERPOL); Fatih Birol, Executive Director, International Energy Agency (IEA); Rebecca Fatima Sta Maria, Executive Director, APEC Secretariat (Asia-Pacific Economic Cooperation).

Christine Lagarde, President, European Central Bank; François Villeroy de Galhau, Governor of the Central Bank of France; Andrew Bailey, Governor of the Bank of England.

The private sector will be represented by more than 1,000 leaders from the Forum’s member and partner organizations. Seven of the top ten companies by market capitalization are engaged year-round with the Forum and many will participate in The Davos Agenda week. As a working meeting to advance ongoing project work, more than 500 chief executives and chairpersons will take part in sessions throughout the week.

Leaders from civil society are a critical voice in shaping the agenda. Those taking part in the meeting include:

Seth Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Gabriela Bucher, Executive Director, Oxfam International; Sharan Burrow, General Secretary, International Trade Union Confederation (ITUC); Hindou Oumarou Ibrahim, President, Association for Indigenous Women and Peoples of Chad (AFPAT); Marco Lambertini, Director-General, WWF International; Laura Liswood, Secretary-General, Council of Women World Leaders; Delia Ferreira Rubio, Chair, Transparency International; Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria (GF). 

Drawn from over 10,000 civic-minded young leaders, members of the World Economic Forum’s Global Shapers, Young Global Leaders, Technology Pioneers and Social Entrepreneurs communities will bring unique perspectives to The Davos Agenda.

Flagship reports, initiatives, and the latest book on Stakeholder Capitalism 

On January 25, Professor Schwab will release his latest book, titled “Stakeholder Capitalism: A Global Economy that Works for Progress, People and Planet.” It explores how societies can build the future post-COVID, and builds on the Forum’s 50-year-old advocacy of the stakeholder approach.

The World Economic Forum will release its Global Risks Report 2021 on 19 January. The flagship report is an important marker for prioritizing action in public and private sectors in the year ahead.

The Davos Agenda will also mark the launch of several World Economic Forum initiatives to accelerate the race to net-zero emissions, to champion new standards for racial justice, to ensure artificial intelligence is developed ethically and in the global public interest and to close the digital divide. More details on these initiatives and others will be disclosed at the meeting.

Opening Event and Crystal Awards

The meeting will be preceded by the Opening Event, available on YouTube on Sunday 24 January at 19.00 CET, featuring a welcome from Klaus Schwab and a special address by Guy Parmelin, President of the Swiss Confederation, just before the 27th Crystal Awards hosted by Hilde Schwab, Chairperson and Co-founder, Schwab Foundation for Social Entrepreneurship, and the photographer Platon.

The awards will be followed by the world premiere of “See Me: A Global Concert.” The official programme of The Davos Agenda will begin on 25 January.

Notes to editors

Media registration and sign-up

Explore the guide on how to follow and embed sessions on your website here

Watch the livestreamed sessions here

Follow the Forum on Twitter via @wef@davos and join the conversation using #DavosAgenda | Instagram | LinkedIn | TikTok | Weibo | Podcasts

Become a fan of the Forum on Facebook

Read the Forum Agenda also in French | Spanish | Mandarin | Japanese

Check out the Forum’s Strategic Intelligence Platform and Transformation Maps

Watch Forum videos

Learn about the Forum’s impact

Subscribe to Forum news releases and Podcasts

SOURCE

From: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Reply-To: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Date: Monday, January 18, 2021 at 9:37 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Read Full Post »

Joe Biden Announced Science Team Nominations for the New Administration

Posted in and Bioethics, Biological Engineering, Evidence-based decision-making, Foundations for supporting Science and Education, Funding Opportunities for Cancer Research, Health Law & Patient Safety, Health Law Policy, HealthCare IT, Interviews with Key Opinion Leaders (KOLs), Leadership, Power, Social Interlocking Connections, National Academy of Sciences AWARDS, Nobel Prize WInners, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, Women in Life Sciences, women in science, tagged , , , , , , , , , , , , , , on January 17, 2021| Leave a Comment »


Joe Biden Announced Science Team Nominations for the New Administration

Reporter: Stephen J. Williams, PhD

 

UPDATED on 1/18/2021

As we move forward, we should all take pride in the continuation of UC Berkeley’s legacy of service and leadership to our political, economic and civic institutions. We congratulate alumni and faculty of the social sciences playing prominent roles in the incoming administration. Dr. Lisa D. Cook (‘04 Ph.D., Economics) is leading the economic transition team. Professor Emeritus Janet Yellen , (Berkeley Haas, Berkeley Economics) is the first woman nominated to serve as Secretary of  the Treasury; Wally Adeyemo (‘03 Political Economy) is the first African-American to serve as the Deputy Secretary of the Treasury; and Alejandro Mayorkas (‘81 History) is both the first Latino American and the first Jewish American nominated as Director of Homeland Security.  

SOURCE

From: Dean Raka Ray <socialsciences@berkeley.edu>

Reply-To: “socialsciences@berkeley.edu” <reply-fe841079776d017a72-101_HTML-19495415-7300855-42@our.berkeley.edu>

Date: Monday, January 18, 2021 at 11:01 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: A message from the Dean of Social Sciences

 

Biden Science Team Nominations

President-elect Joe Biden and Vice President-elect Kamala Harris announced several members of their White House science team. Eric Lander is the nominee for director of the Office of Science and Technology Policy, elevated to a Cabinet-level position. Mr. Biden also selected Alondra Nelson for deputy director of the President’s Council of Advisers on Science and Technology, and appointed Frances Arnold and Maria Zuber as co-chairs of the Office of Science and Technology Policy. 

 

 

In an announcement televised on C-Span, President Elect Joseph Biden announced his new Science Team to advise on science policy matters, as part of the White House Advisory Committee on Science and Technology. Below is a video clip and the transcript, also available at

https://www.c-span.org/video/?508044-1/president-elect-biden-introduces-white-house-science-team

The video link is

https://www.c-span.org/video/?508044-1/president-elect-biden-introduces-white-house-science-team

 

 

COMING UP TONIGHT ON C-SPAN, NEXT, PRESIDENT-ELECT JOE BIDEN AND VICE PRESIDENT-ELECT KAMALA HARRIS ANNOUNCE SEVERAL MEMBERS OF THEIR WHITE HOUSE SCIENCE TEAM. AND THEN SENATE MINORITY LEADER CHUCK SCHUMER TALKS ABOUT THE IMPEACHMENT OF PRESIDENT TRUMP IN THE WEEKLY DEMOCRATIC ADDRESS. AND AFTER THAT, TODAY’S SPEECH BY VICE PRESIDENT MIKE PENCE TO SAILORS AT NAVAL AIR STATION LAMORE IN CALIFORNIA. NEXT, PRESIDENT-ELECT JOE BIDEN AND VICE PRESIDENT-ELECT KAMALA HARRIS ANNOUNCE SEVERAL MEMBERS OF THEIR WHITE HOUSE SCIENCE TEAM. FROM WILMINGTON, DELAWARE, THIS IS ABOUT 40 MINUTES. PRESIDENT-ELECT BIDEN: GOOD AFTERNOON, FOLKS. I WAS TELLING THESE FOUR BRILLIANT SCIENTISTS AS I STOOD IN THE BACK, IN A WAY, THEY — THIS IS THE MOST EXCITING ANNOUNCEMENT THAT I’VE GOTTEN TO MAKE IN THE ENTIRE CABINET RAISED TO A CABINET LEVEL POSITION IN ONE CASE. THESE ARE AMONG THE BRIGHTEST MOST DEDICATED PEOPLE NOT ONLY IN THE COUNTRY BUT THE WORLD. THEY’RE COMPOSED OF SOME OF THE MOST SCIENTIFIC BRILLIANT MINDS IN THE WORLD. WHEN I WAS VICE PRESIDENT AS — I I HAD INTENSE INTEREST IN EVERYTHING THEY WERE DOING AND I PAID ENORMOUS ATTENTION. AND I WOULD — LIKE A KID GOING BACK TO SCHOOL. SIT DOWN AND CAN YOU EXPLAIN TO ME AND THEY WERE — VERY PATIENT WITH ME. AND — BUT AS PRESIDENT, I WANTED YOU TO KNOW I’M GOING TO PAY A GREAT DEAL OF ATTENTION. WHEN I TRAVEL THE WORLD AS VICE PRESIDENT, I WAS OFTEN ASKED TO EXPLAIN TO WORLD LEADERS, THEY ASKED ME THINGS LIKE DEFINE AMERICA. TELL ME HOW CAN YOU DEFINE AMERICA? WHAT’S AMERICA? AND I WAS ON A TIBETAN PLATEAU WITH AT THE TIME WITH XI ZIN PING AND WE HAD AN INTERPRETER CAN I DEFINE AMERICA FOR HIM? I SAID YES, I CAN. IN ONE WORD. POSSIBILITIES. POSSIBILITIES. I THINK IT’S ONE OF THE REASONS WHY WE’VE OCCASIONALLY BEEN REFERRED TO AS UGLY AMERICANS. WE THINK ANYTHING’S POSSIBLE GIVEN THE CHANCE, WE CAN DO ANYTHING. AND THAT’S PART OF I THINK THE AMERICAN SPIRIT. AND WHAT THE PEOPLE ON THIS STAGE AND THE DEPARTMENTS THEY WILL LEAD REPRESENT ENORMOUS POSSIBILITIES. THEY’RE THE ONES ASKING THE MOST AMERICAN OF QUESTIONS, WHAT NEXT? WHAT NEXT? NEVER SATISFIED, WHAT’S NEXT? AND WHAT’S NEXT IS BIG AND BREATHTAKING. HOW CAN — HOW CAN WE MAKE THE IMPOSSIBLE POSSIBLE? AND THEY WERE JUST ASKING QUESTIONS FOR THE SAKE OF QUESTIONS, THEY’RE ASKING THESE QUESTIONS AS CALL TO ACTION. , TO INSPIRE, TO HELP US IMAGINE THE FUTURE AND FIGURE OUT HOW TO MAKE IT REAL AND IMPROVE THE LIVES OF THE AMERICAN PEOPLE AND PEOPLE AROUND THE WORLD. THIS IS A TEAM THAT ASKED US TO IMAGINE EVERY HOME IN AMERICA BEING POWERED BY RENEWABLE ENERGY WITHIN THE NEXT 10 YEARS. OR 3-D IMAGE PRINTERS RESTORING TISSUE AFTER TRAUMATIC INJURIES AND HOSPITALS PRINTING ORGANS FOR ORGAN TRANSPLANTS. IMAGINE, IMAGINE. AND THEY REALLY — AND, YOU KNOW, THEN RALLY, THE SCIENTIFIC COMMUNITY TO GO ABOUT DOING WHAT WE’RE IMAGINING. YOU NEED SCIENCE, DATA AND DISCOVERY WAS A GOVERNING PHILOSOPHY IN THE OBAMA-BIDEN ADMINISTRATION. AND EVERYTHING FROM THE ECONOMY TO THE ENVIRONMENT TO CRIMINAL JUSTICE REFORM AND TO NATIONAL SECURITY. AND ON HEALTH CARE. FOR EXAMPLE, A BELIEF IN SCIENCE LED OUR EFFORTS TO MAP THE HUMAN BRAIN AND TO DEVELOP MORE PRECISE INDIVIDUALIZED MEDICINES. IT LED TO OUR ONGOING MISSION TO END CANCER AS WE KNOW IT, SOMETHING THAT IS DEEPLY PERSONAL TO BOTH MY FAMILY AND KAMALA’S FAMILY AND COUNTLESS FAMILIES IN AMERICA. WHEN PRESIDENT OBAMA ASKED ME TO LEAD THE CANCER MOON SHOT, I KNEW WE HAD TO INJECT A SENSE OF URGENCY INTO THE FIGHT. WE BELIEVED WE COULD DOUBLE THE RATE OF PROGRESS AND DO IN FIVE YEARS WHAT OTHERWISE WOULD TAKE 10. MY WIFE, JILL, AND I TRAVELED AROUND THE COUNTRY AND THE WORLD MEETING WITH THOUSANDS OF CANCER PATIENTS AND THEIR FAMILIES, PHYSICIANS, RESEARCHERS, PHILANTHROPISTS, TECHNOLOGY LEADERS AND HEADS OF STATE. WE SOUGHT TO BETTER UNDERSTAND AND BREAK DOWN THE SILOS AND STOVE PIPES THAT PREVENT THE SHARING OF INFORMATION AND IMPEDE ADVANCES IN CANCER RESEARCH AND TREATMENT WHILE BUILDING A FOCUSED AND COORDINATED EFFORT HERE AT HOME AND ABROAD. WE MADE PROGRESS. BUT THERE’S SO MUCH MORE THAT WE CAN DO. WHEN I ANNOUNCED THAT I WOULD NOT RUN IN 2015 AT THE TIME, I SAID I ONLY HAD ONE REGRET IN THE ROSE GARDEN AND IF I HAD ANY REGRETS THAT I HAD WON, THAT I WOULDN’T GET TO BE THE PRESIDENT TO PRESIDE OVER CANCER AS WE KNOW IT. WELL, AS GOD WILLING, AND ON THE 20TH OF THIS MONTH IN A COUPLE OF DAYS AS PRESIDENT I’M GOING TO DO EVERYTHING I CAN TO GET THAT DONE. I’M GOING TO — GOING TO BE A PRIORITY FOR ME AND FOR KAMALA AND IT’S A SIGNATURE ISSUE FOR JILL AS FIRST LADY. WE KNOW THE SCIENCE IS DISCOVERY AND NOT FICTION. AND IT’S ALSO ABOUT HOPE. AND THAT’S AMERICA. IT’S IN THE D.N.A. OF THIS COUNTRY, HOPE. WE’RE ON THE CUSP OF SOME OF THE MOST REMARKABLE BREAKTHROUGHS THAT WILL FUNDAMENTALLY CHANGE THE WAY OF LIFE FOR ALL LIFE ON THIS PLANET. WE CAN MAKE MORE PROGRESS IN THE NEXT 10 YEARS, I PREDICT, THAN WE’VE MADE IN THE LAST 50 YEARS. AND EXPONENTIAL MOVEMENT. WE CAN ALSO FACE SOME OF THE MOST DIRE CRISES IN A GENERATION WHERE SCIENCE IS CRITICAL TO WHETHER OR NOT WE MEET THE MOMENT OF PERIL AND PROMISE THAT WE KNOW IS WITHIN OUR REACH. IN 1944, FRANKLIN ROOSEVELT ASKED HIS SCIENCE ADVISOR HOW COULD THE UNITED STATES FURTHER ADVANCE SCIENTIFIC RESEARCH IN THE CRITICAL YEARS FOLLOWING THE SECOND WORLD WAR? THE RESPONSE LED TO SOME OF THE MOST GROUND BREAKING DISCOVERIES IN THE LAST 75 YEARS. AND WE CAN DO THAT AGAIN. AND WE CAN DO MORE. SO TODAY, I’M PROUD TO ANNOUNCE A TEAM OF SOME OF THE COUNTRY’S MOST BRILLIANT AND ACCOMPLISHED SCIENTISTS TO LEAD THE WAY. AND I’M ASKING THEM TO FOCUS ON FIVE KEY AREAS. FIRST THE PANDEMIC AND WHAT WE CAN LEARN ABOUT WHAT IS POSSIBLE OR WHAT SHOULD BE POSSIBLE TO ADDRESS THE WIDEST RANGE OF PUBLIC HEALTH NEEDS. SECONDLY, THE ECONOMY, HOW CAN WE BUILD BACK BETTER TO ENSURE PROSPERITY IS FULLY SHARED ALL ACROSS AMERICA? AMONG ALL AMERICANS? AND THIRDLY, HOW SCIENCE HELPS US CONFRONT THIS CLIMATE CRISIS WE FACE IN AMERICA AND THE WORLD BUT IN AMERICA HOW IT HELPS US CONFRONT THE CLIMATE CRISIS WITH AMERICAN JOBS AND INGENUITY. AND FOURTH, HOW CAN WE ENSURE THE UNITED STATES LEADS THE WORLD IN TECHNOLOGIES AND THE INDUSTRIES THAT THE FUTURE THAT WILL BE CRITICAL FOR OUR ECONOMIC PROSPERITY AND NATIONAL SECURITY? ESPECIALLY WITH THE INTENSE INCREASED COMPETITION AROUND THE WORLD FROM CHINA ON? AND FIFTH, HOW CAN WE ASSURE THE LONG-TERM HEALTH AND TRUST IN SCIENCE AND TECHNOLOGY IN OUR NATION? YOU KNOW, THESE ARE EACH QUESTIONS THAT CALL FOR ACTION. AND I’M HONORED TO ANNOUNCE A TEAM THAT IS ANSWERING THE CALL TO SERVE. AS THE PRESIDENTIAL SCIENCE ADVISOR AND DIRECTOR OF THE OFFICE OF SCIENCE AND TECHNOLOGY POLICY, I NOMINATE ONE OF THE MOST BRILLIANT GUYS I KNOW, PERSONS I KNOW, DR. ERIC LANDER. AND THANK YOU, DOC, FOR COMING BACK. THE PIONEER — HE’S A PIONEER IN THE STIFFING COMMUNITY. PRINCIPAL LEADER IN THE HUMAN GENOME PROJECT. AND NOT HYPERBOLE TO SUGGEST THAT DR. LANDER’S WORK HAS CHANGED THE COURSE OF HUMAN HISTORY. HIS ROLE IN HELPING US MAP THE GENOME PULLED BACK THE CURTAIN ON HUMAN DISEASE, ALLOWING SCIENTISTS, EVER SINCE, AND FOR GENERATIONS TO COME TO EXPLORE THE MOLECULAR BASIS FOR SOME OF THE MOST DEVASTATING ILLNESSES AFFECTING OUR WORLD. AND THE APPLICATION OF HIS PIONEERING WORK AS — ARE POISED TO LEAD TO INCREDIBLE CURES AND BREAKTHROUGHS IN THE YEARS TO COME. DR. LANDER NOW SERVES AS THE PRESIDENT AND FOUNDING DIRECTOR OF THE BRODE INSTITUTE AT M.I.T. AND HARVARD, THE WORLD’S FOREMOST NONPROFIT GENETIC RESEARCH ORGANIZATION. AND I CAME TO APPRECIATE DR. LANDER’S EXTRAORDINARY MIND WHEN HE SERVED AS THE CO-CHAIR OF THE PRESIDENT’S COUNCIL ON ADVISORS AND SCIENCE AND TECHNOLOGY DURING THE OBAMA-BIDEN ADMINISTRATION. AND I’M GRATEFUL, I’M GRATEFUL THAT WE CAN WORK TOGETHER AGAIN. I’VE ALWAYS SAID THAT BIDEN-HARRIS ADMINISTRATION WILL ALSO LEAD AND WE’RE GOING TO LEAD WITH SCIENCE AND TRUTH. WE BELIEVE IN BOTH. [LAUGHTER] GOD WILLING OVERCOME THE PANDEMIC AND BUILD OUR COUNTRY BETTER THAN IT WAS BEFORE. AND THAT’S WHY FOR THE FIRST TIME IN HISTORY, I’M GOING TO BE ELEVATING THE PRESIDENTIAL SCIENCE ADVISOR TO A CABINET RANK BECAUSE WE THINK IT’S THAT IMPORTANT. AS DEPUTY DIRECTOR OF THE OFFICE OF SCIENCE AND TECHNOLOGY POLICY AND SCIENCE AND — SCIENCE AND SOCIETY, I APPOINT DR. NELSON. SHE’S A PROFESSOR AT THE INSTITUTE OF ADVANCED STUDIES AT PRINCETON UNIVERSITY. THE PRESIDENT OF THE SOCIAL SCIENCE RESEARCH COUNCIL. AND ONE OF AMERICA’S LEADING SCHOLARS IN THE — AN AWARD-WINNING AUTHOR AND RESEARCHER AND EXPLORING THE CONNECTIONS BETWEEN SCIENCE AND OUR SOCIETY. THE DAUGHTER OF A MILITARY FAMILY, HER DAD SERVED IN THE UNITED STATES NAVY AND HER MOM WAS AN ARMY CRIPPING TO RAFFER. DR. NELSON DEVELOPED A LOVE OF TECHNOLOGY AT A VERY YOUNG AGE PARTICULARLY WITH THE EARLY COMPUTER PRODUCTS. COMPUTING PRODUCTS AND CODE-BREAKING EQUIPMENT THAT EVERY KID HAS AROUND THEIR HOUSE. AND SHE GREW UP WITHIN HER HOME. WHEN I WROTE THAT DOWN, I THOUGHT TO MYSELF, I MEAN, HOW MANY KIDS — ANY WAY, THAT PASSION WAS A PASSION FORGED A LIFELONG CURIOSITY ABOUT THE INEQUITIES AND THE POWER DIAMONDICS THAT SIT BENEATH THE SURFACE OF SCIENTIFIC RESEARCH AND THE TECHNOLOGY WE BUILD. DR. NELSON IS FOCUSED ON THOSE INSIGHTS. AND THE SCIENCE, TECHNOLOGY AND SOCIETY, LIKE FEW BEFORE HER EVER HAVE IN AMERICAN HISTORY. BREAKING NEW GROUND ON OUR UNDERSTANDING OF THE ROLE SCIENCE PLAYS IN AMERICAN LIFE AND OPENING THE DOOR TO — TO A FUTURE WHICH SCIENCE BETTER SERVES ALL PEOPLE. AS CO-CHAIR OF THE PRESIDENT’S COUNCIL ON ADVISORS OF SCIENCE AND TECHNOLOGY, I APPOINT DR. FRANCIS ARNOLD, DIRECTOR OF THE ROSE BIOENGINEERING CENTER AT CALTECH AND ONE OF THE WORLD’S LEADING EXPERTS IN PROTEIN ENGINEERING, A LIFE-LONG CHAMPION OF RENEWABLE ENERGY SOLUTIONS WHO HAS BEEN INDUCTED INTO THE NATIONAL INVENTORS’ HALL OF FAME. THAT AIN’T A BAD PLACE TO BE. NOT ONLY IS SHE THE FIRST WOMAN TO BE ELECTED TO ALL THREE NATIONAL ACADEMIES OF SCIENCE, MEDICINE AND ENGINEERING AND ALSO THE FIRST WOMAN, AMERICAN WOMAN, TO WIN A NOBEL PRIZE IN CHEMISTRY. A VERY SLOW LEARNER, SLOW STARTER, THE DAUGHTER OF PITTSBURGH, SHE WORKED AS A CAB DRIVER, A JAZZ CLUB SERVER, BEFORE MAKING HER WAY TO BERKELEY AND A CAREER ON THE LEADING EDGE OF HUMAN DISCOVERY. AND I WANT TO MAKE THAT POINT AGAIN. I WANT — IF ANY OF YOUR CHILDREN ARE WATCHING, LET THEM KNOW YOU CAN DO ANYTHING. THIS COUNTRY CAN DO ANYTHING. ANYTHING AT ALL. AND SO SHE SURVIVED BREAST CANCER, OVERCAME A TRAGIC LOSS IN HER FAMILY WHILE RISING TO THE TOP OF HER FIELD, STILL OVERWHELMINGLY DOMINATED BY MEN. HER PASSION HAS BEEN A STEADFAST COMMITMENT TO RENEWABLE ENERGY FOR THE BETTERMENT OF OUR PLANET AND HUMANKIND. SHE IS AN INSPIRING FIGURE TO SCIENTISTS ACROSS THE FIELD AND ACROSS NATIONS. AND I WANT TO THANK DR. ARNOLD FOR AGREEING TO CO-CHAIR A FIRST ALL WOMAN TEAM TO LEAD THE PRESIDENT’S COUNCIL OF ADVISORS ON SCIENCE AND TECHNOLOGY WHICH LEADS ME TO THE NEXT MEMBER OF THE TEAM. AS CO-CHAIR, THE PRESIDENT’S COUNCIL OF ADVISORS ON SCIENCE AND TECHNOLOGY, I APPOINT DR. MARIE ZUBER. A TRAIL BLAZER BRAISING GEO PHYSICIST AND PLANETARY SCIENTIST A. FORMER CHAIR OF THE NATIONAL SCIENCE BOARD. FIRST WOMAN TO LEAD THE SCIENCE DEPARTMENT AT M.I.T. AND THE FIRST WOMAN TO LEAD NASA’S ROBOTIC PLANETARY MISSION. GROWING UP IN COLE COUNTRY NOT FAR FROM HEAVEN, SCRANTON, PENNSYLVANIA, IN CARBON COUNTY, PENNSYLVANIA, ABOUT 50 MILES SOUTH OF WHERE I WAS A KID, SHE DREAMED OF EXPLORING OUTER SPACE. COULD HAVE TOLD HER SHE WOULD JUST GO TO GREEN REACH IN SCRANTON AND FIND WHERE IT WAS. AND I SHOULDN’T BE SO FLIPPANT. BUT I’M SO EXCITED ABOUT THESE FOLKS. YOU KNOW, READING EVERY BOOK SHE COULD FIND AND LISTENING TO HER MOM’S STORIES ABOUT WATCHING THE EARLIEST ROCKET LAUNCH ON TELEVISION, MARIE BECAME THE FIRST PERSON IN HER FAMILY TO GO TO COLLEGE AND NEVER LET GO OF HER DREAM. TODAY SHE OVERSEES THE LINCOLN LABORATORY AT M.I.T. AND LEADS THE INSTITUTION’S CLIMATE ACTION PLAN. GROWING UP IN COLD COUNTRY, NOT AND FINALLY, COULD NOT BE HERE TODAY, BUT I’M PLEASED TO ANNOUNCE THAT I’VE HAD A LONG CONVERSATION WITH DR. FRANCIS COLLINS AND COULD NOT BE HERE TODAY. AND I’VE ASKED THEM TO STAY ON AS DIRECTOR OF THE INSTITUTE OF HEALTH AND — AT THIS CRITICAL MOMENT. I’VE KNOWN DR. COLLINS FOR MANY YEARS. I WORKED WITH HIM CLOSELY. HE’S BRILLIANT. A PIONEER. A TRUE LEADER. AND ABOVE ALL, HE’S A MODEL OF PUBLIC SERVICE AND I’M HONORED TO BE WORKING WITH HIM AGAIN. AND IT IS — IN HIS ABSENCE I WANT TO THANK HIM AGAIN FOR BEING WILLING TO STAY ON. I KNOW THAT WASN’T HIS ORIGINAL PLAN. BUT WE WORKED AN AWFUL LOT ON THE MOON SHOT AND DEALING WITH CANCER AND I JUST WANT TO THANK HIM AGAIN. AND TO EACH OF YOU AND YOUR FAMILIES, AND I SAY YOUR FAMILIES, THANK YOU FOR THE WILLINGNESS TO SERVE. AND NOT THAT YOU HAVEN’T BEEN SERVING ALREADY BUT TO SERVE IN THE ADMINISTRATION. AND THE AMERICAN PEOPLE, TO ALL THE AMERICAN PEOPLE, THIS IS A TEAM THAT’S GOING TO HELP RESTORE YOUR FAITH IN AMERICA’S PLACE IN THE FRONTIER OF SCIENCE AND DISCOVER AND HOPE. I’M NOW GOING TO TURN THIS OVER STARTING WITH DR. LANDER, TO EACH OF OUR NOMINEES AND THEN WITH — HEAR FROM THE VICE PRESIDENT. BUT AGAIN, JUST CAN’T THANK YOU ENOUGH AND I REALLY MEAN IT. THANK YOU, THANK YOU, THANK YOU FOR WILLING TO DO THIS. DOCTOR, IT’S ALL YOURS. I BETTER PUT MY MASK ON OR I’M GOING TO GET IN TROUBLE.

 

Director’s Page

Read Full Post »

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures: Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track  

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on January 6, 2021| Leave a Comment »


Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track

 

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

 

UPDATED on 1/21/2021

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

 

* Call for Top Innovators Details below

 

 

Venture Summit Virtual Connect West

Where Innovation Meets Capital

 

March 16th -18th 2021

 

 

Friends,

 

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.

 

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

 

Partial roster of over VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Sion Balass, Partner, The Group Ventures | Randy Berholtz, Senior Advisor, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Udit Bhatnagar, Vice President, McRock Capital | Christopher Booker, Partner, Frist Cressey Ventures | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Jun Deng, Investment Partner, Joyance Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Elena Gantvarg, Principal, Flint Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | David Goldberg, General Partner, Alpaca VC | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Katie Hayes, Director, Wittington Ventures | Robert Hess, Angel Investor, Life Science Angels | Kirsten Horning, Principal, XRC Labs | Ben Jen, Managing Director, Ben Jen Holdings | Hunter Kettering, VC, Red Cedar Ventures | Howard Ko, Principal, Morpheus Ventures | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Americas | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Molly O’Shea, Investor, NYL Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Daniel Pianko, Managing Director, Achieve Partners | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | John Robinson, Partner, Mazarine Ventures | Stephen Roland, Associate, Swiftarc Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Massimo Schäppi, Partner, Tomahawk .VC | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Byron Thom, Principal, Framework Venture Partners | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Lauren Weston, Associate, Thomvest Ventures | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

 

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here http://bit.ly/3840e3D    . (Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 

We look forward to seeing you there.

 

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures

 

 

 

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

 

* Call for Top Innovators Details below

  

Venture Summit Virtual Connect West

Where Innovation Meets Capital

 

March 16th -18th 2021

Register Today & Save

Click here http://bit.ly/3840e3D   

(Use promo code “LPBIVIP”)

Friends,

 

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss. 

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

 

Partial roster of VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Timur Davis, Principal, Munich Re Ventures | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Andrew Felbinger, Investor, Urban Innovation Fund | Gary Gershony, Founding General Partner, BayMed Venture Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Kirsten Horning, Principal, XRC Labs | Hunter Kettering, VC, Red Cedar Ventures | Rachel Lauren, Analyst, BDMI | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Matt Murphy, Partner, Montage Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nia Stefani, CEO, Xnergy Financial | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here http://bit.ly/3840e3D   

(Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

  

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here. 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

  

We look forward to seeing you there.

 

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

 

 

 

 

 

LinkedIn

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Whether you are a Lifesciences / Healthcare investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

 

Twitter

Join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences/Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Where do #startups connect with over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register at  http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Facebook

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

 

 

Read Full Post »

Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as CEO and Arie Belldegrun, PhD on R&D

Posted in Bio Instrumentation in Experimental Life Sciences Research, Biological Engineering, Biological Networks, Gene Regulation and Evolution, Biomedical Measurement Science, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Gene Regulation, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Genomics Pharmacy on October 15, 2020| Leave a Comment »


Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D

Curator & Reporter: Aviva Lev-Ari, PhD, RN

 

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

A new approach to biology

“The real voyage of discovery consists, not in seeking new landscapes, but in having new eyes.” Marcel Proust

Starting with the study of P granules in C.elegans embryos in 2009, Tony Hyman, working with his collaborators like Frank Julicher, Cliff Brangwynne, Simon Alberti, Mike Rosen, and Rohit Pappu, began to unravel the mysteries of biomolecular condensates. These scientists realized that P granules behave like liquid droplets that form by phase separation (think of oil droplets in salad dressing) and called them condensates.

In subsequent studies, they found to their surprise that many compartments inside cells had the behavior of condensates: they are liquid-like and form by phase separation.

Inspired by the work of Tony and his colleagues, Richard Young, Phillip Sharp, and Arup Chakraborty at MIT applied these approaches to the study of gene expression, similarly shedding light on many important questions in gene control.

a video thumbnail

Rick Young on condensates and gene control.

a video thumbnail

Tony Hyman on how cells form compartments. (From LatestThinking.org via CC BY 4.0; trimmed for length.)

Foundational Papers in Biomolecular Condensates

Germline P granules are liquid droplets that localize by controlled dissolution/condensation (Science, June 2009)

Liquid-Liquid Phase Separation in Biology (Annual Review of Cell & Developmental Biology, Oct 2014)

A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation (Cell, Aug 2015)

Biomolecular condensates: organizers of cellular biochemistry (Nature Review Cell Biology, Feb 2017)

A Phase Separation Model for Transcriptional Control. (Cell, March 2017)

Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains (Cell, Nov 2018)

SOURCE

https://dewpointx.com/

 

Press releases and Dewpoint in the news

 

  • Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer

    Dewpoint

  • New York Times interviews Rick Young and Amy Gladfelter on the role of condensate “droplets” in COVID-19

    New York Times

  • Dewpoint Therapeutics raises $77 million to go after ‘undruggable’ diseases

    Boston Globe

  • Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

    Endpoint News

  • Dewpoint Therapeutics to put ‘pedal to the metal’ with $77M round

    FierceBiotech

  • Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates

    Dewpoint

  • 21 biotech startups that are set to take off, according to top VCs

    Business Insider

  • Proteins — and labs — coming together to prevent Rett Syndrome

    Whitehead Institute

  • Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

    Dewpoint

  • Discovery of how cancer drugs find their targets could lead to a new toolset for drug development

    Whitehead Institute

SOURCE

https://dewpointx.com/news/

Other related article published in this Online Open Access Scientific Journal include: 

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

Read Full Post »

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Posted in Big Data, BioSimilars, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, drug repurposing, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment on September 4, 2020| 1 Comment »


Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma &amp; Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

 

e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

Founder & Director, LPBI Group

https://pharmaceuticalintelligence.com/2020/07/28/14th-annual-biopharma-healthcare-summit-friday-september-4-2020-8-am-est-to-3-30-pm-est-virtual-edition/

 

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline GWAS not easy to find which gene drives the association  Functional Genomics gene by gene with phenotypes using machine learning significant help

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK GWAS not easy to find which gene drives the association  Functional Genomics gene by gene with phenotypes using machine learning significant help

You Retweeted

Srihari Gopal
@sgopal2

Enjoyed hearing enthusiasm for Neuroscience R&D by Roy Vagelos at #USAIC20. Wonderful interview by Mathai Mammen

@JanssenGlobal

Image

1
2
Show this thread

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Nina Kjellson, General Partner, Canaan Data science is a winner in Healthcare Women – Data Science is an excellent match

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co. Data on Patients and identification who will benefit fro which therapy  cultural bias risk aversion

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson Data Validation  Deployment of algorithms embed data by type early on in the crisis to understand the disease

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Sastry Chilukuri, President, Acorn AI- Medidata Opportunities in Data Science in Paharma COVID-19 and Data Science

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Maya Said, Chief Executive Officer, Outcomes4Me Cancer patients taking change of their care Digital Health – consumerization of Health, patient demand to be part of the decision, part the information FDA launched a Program Project Patient Voice

You Retweeted

USAIC
@USAIC

We’re taking a quick break at #USAIC20 before our next panel on rare diseases starts at 12:20pm EDT. USAIC would like to thank our Sponsors and Partners for supporting this year’s digital event.

Image

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals Congratulates Big Pharma for taking the challenge on COVID-19 Vaccine, Antibody and anti-viral Government funding Merck was independent from Government – to be able to set the price

1
You Retweeted

Dr Kapil Khambholja
@kapilmk

Christopher Viehbacher, Gurnet Point Capital touches very sensitive topic at #USAIC20 He claims that we are never going to have real innovation out of big pharma! Well this isn’t new but not entirely true either… any more thoughts?
1
1
Show this thread

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Daphne Zohar, Founder & CEO, PureTech Health Disease focus, best science is the decision factors

1

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Christopher Viehbacher, Managing Partner, Gurnet Point Capital Dream of every Biotech – get Big Pharma coming to acquire and pay a lot Morph and adapt

You Retweeted

anju ghangurde
@scripanjug

Biogen’s chair Papadopoulos big co mergers is an attempt to solve problems; typically driven by patent expirations.. #usaic20

@USAIC
2
You Retweeted

anju ghangurde
@scripanjug

Chris Viehbacher/Gurnet Point Capital on US election: industry will work with whoever wins; we’ll have to ‘morph & adapt’ #usaic20

@USAIC
1
You Retweeted

Dr Kapil Khambholja
@kapilmk

@daphnezohar

of

@PureTechH

talks about various philosophies and key reasons why certain projects/molecules are killed early. My counter questions- What are chances of losing hope little early? Do small #biopharma publish negative results to aid to the knowledge pool? #USAIC20

Image

2
2
Show this thread

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute DNA repair and epignetics are the future of medicine

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute COlonorectal cancer is increasing immuno therapy 5 drugs marketed 30% cancer patients are treated early detection key vs metastatic 10% of cancer are inherited treatment early

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono Charities funding cancer research – were impacted and resources will come later and in decreased amount New opportunities support access to Medicine improve investment across the board

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Philip Larsen, Global Head of Research, Bayer AG Repurposing drugs as antiviral from drug screening innovating methods Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral data of tested positive allows research of pathway in new ways

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber 3,000 Telemedicine session in the first week of the Pandemic vs 300 before – patient come back visits patient happy with Telemedicine team virtually need be reimbursed same rate working remotely

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School New normal as a result of the pandemic role of personalized medicine

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono entire volume of clinical trials at Roche went down same at EMD delay of 6 month, some were to be initiated but was put on hold Charities funding cancer research were impacted and resources will come later smaller

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute Dana Farber saw impact of COVID-19 on immunosuppressed patients coming in for Cancer Tx – switch from IV Tx to Oral 96% decrease in screenings due to Pandemic – increase with Cancer

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Pharma’s obligation for next generations requires investment in R&D vs Politicians running for 4 years Patients must come first vs shareholders vs R&D investment in 2011

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics people will die from bacterial resistance next pandemic be bacterial

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit” – Ketruda in India is not reembureable in India and million are in need it Partnership are encouraged

You Retweeted

Dr Kapil Khambholja
@kapilmk

@biogen

Chairman Stelios Papadopoulos asks #KennethFrazier if wealthy nations will try to secure large proportion of #COVID19 drugs/vaccines. #KennethFrazie rightly mentions: pharma industry’s responsibility to balance the access to diff countries during pandemic. #USAIC20

1
3
Show this thread
You Retweeted

Dr Kapil Khambholja
@kapilmk

Almost 60% participants at #USAIC20 feel that MNCs are more likely to run their #clinicalTrials in #INDIA seeing changing environment here, reveals the poll. Exciting time ahead for scientific fraternity as this can substantially increase the speed of #DrugDevelopment globally

Clapping hands sign

Image

1
1
Show this thread

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Vaccine in clinical trials, public need to return for 2nd shot, hesitancy Who will get the Vaccine first in the US  most vulnerable of those causing transmission Pharma’s risk

4

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred Antibody testing CRISPR test based Vaccine in clinical trials

1

Aviva Lev-Ari
@AVIVA1950

@pharma_BI
@AVIVA1950

#USAIC20 Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals COllaboration effort around the Globe in the Pandemic therapy solutions including Vaccines

Read Full Post »

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Posted in BioTechnology - Venture Creation, Conference Coverage with Social Media, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on July 28, 2020| 1 Comment »


14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

Founder & Director, LPBI Group

 

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma &amp; Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/09/04/tweet-collection-by-pharma_bi-and-aviva1950-and-re-tweets-for-e-proceedings-14th-annual-biopharma-healthcare-summit-friday-september-4-2020-8-am-est-to-3-30-pm-est-virtual-editio/

 

 

 

http://www.usaindiachamber.org

 

 2021 summit- June 22. Marriott Cambridge, Massachusetts, USA

 

LPBI’s 2020 VISION

@pharma_BI

@AVIVA1950

#USAIC20

 

 

USAIC has created an ecosystem committed to driving a global dialogue on BioPharma & Healthcare innovation, attracting a diverse mix of senior industry professionals and catalyzing partnerships, new ideas, networks and regulatory reform. This unique platform creates mutually beneficial opportunities and relationships for the global Life Sciences & Healthcare industry.

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

 

Speakers

Kenneth Frazier
Chairman of the Board & CEO
Merck & Co.
Dr. Andrew Plump
President of R&D
Takeda Pharmaceuticals
Dr. Laurie Glimcher
President & CEO
Dana-Farber Cancer Institute
Dr. Roy Vagelos
Chairman of the Board
Regeneron
Dr. Stelios Papadopoulos
Chairman of the Board
Biogen

Dr. Mathai Mammen
Global Head of Janssen R&D
Johnson & Johnson
Christopher Viehbacher
Managing Partner
Gurnet Point Capital
Hari Bhartia
Founder & Co-Chairman
Jubilant Bhartia Group
Dr. Hal Barron
President, R&D and CSO
GlaxoSmithKline
Prof. K. Vijay Raghavan
Principal Scientific Advisor
Government of India

Sanat Chattopadhyay
President- Merck Manufacturing Division
Merck & Co.
Dr. George Yancopoulos
Co-Founder, President & CSO
Regeneron
Kiran Mazumdar Shaw
Executive Chairperson
Biocon
Dr. Elias Zerhouni
Professor Emeritus
Johns Hopkins University
Dr. David Reese
Executive Vice President- R&D
Amgen

Dr. Alfred Sandrock
Executive Vice President, R&D
Biogen
Dr. Naresh Trehan
Chairman
Medanta – the Medicity
Dr. Najat Khan
Chief Operating Officer, Data Sciences
Janssen- Johnson & Johnson
Dr. Richard Hatchett
Chief Executive Officer
CEPI
Amitabh Kant
Chief Executive Officer
NITI Aayog

Dr. Martin Mackay
Co-Founder
Rallybio
Dr. Daniel Curran
Head of the Rare Diseases TA
Takeda Pharmaceuticals
Daphne Zohar
Founder & CEO
PureTech Health
Dr. David Meeker
Chairman & CEO
Rhythm Pharmaceuticals
Dr. John Orloff
EVP and Head of R&D
Alexion

Dr. Mandeep Bhandari
Joint Secretary
Ministry of Health, India
Dr. Barry Bloom
Professor & former Dean
Harvard School of Public Health
Dr. Anne Heatherington
Head of Data Sciences Institute
Takeda Pharmaceuticals
Dr. Philip Larsen
Global Head of Research
Bayer AG
Dr. Timothy Yu
Assistant Professor in Pediatrics
Harvard Medical School

Rehan Verjee
President
EMD Serono
Sastry Chilukuri
Executive Vice President
Medidata
Arpa Garay
President, Commercial Analytics
Merck & Co.
Dr. William Chin
Professor of Medicine, Emeritus
Harvard Medical School
Dr. V G Somani
Drugs Controller General of India
Government of India

Dr. Rajeev Venkayya
President-Global Vaccines
Takeda
Dr. Steve Uden
Co-Founder
Rallybio
Muna Bhanji
SVP, Global Market Access
Merck & Co.
Dr. Maya Said
Chief Executive Officer
Outcomes4Me
Dr. Raju Kucherlapati
Professor of Genetics
Harvard Medical School

Dr. Tony Ho
Head of R&D
CRISPR Therapeutics
Dr. Sanjeev Sinha
Professor of Medicine
All India Institute of Medical Sciences
Nina Kjellson
General Partner
Canaan
Dr. Michael Rosenblatt
Chief Medical Officer
Flagship Pioneering
Dr. Shiv Kumar Sarin
Director
Institute of Liver & Biliary Sciences

Matt Wilsey
Co-Founder & Chairman
Grace Science Foundation
Dr. Samuel Waksal
Founder
Meira GTx
Dr. Alise Reicin
Former President, Global Clinical Dev.
Celgene
Dr. Toni Choueiri
Director
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Dr. Dhaval Patel
EVP & Chief Scientific Officer
UCB

Dr. Nirmal Kumar Ganguly
Former Director General
Indian Council of Medical Research
Dr. Peter Mueller
President
The Muller Health Foundation
Dr. Timothy Clackson
President & CTO
Xilio Therapeutics
 

 

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020,

8 AM EST to 3-30 PM EST – Virtual Edition

 

Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals

Timings are Eastern Standard Time (EST)

Time Topic
8 AM – 8-10 AM Welcome address: Karun Rishi, President, USAIC

  • COVID-19 Pandemic is a Global crisis
  • India can play a special role in R&D and in Manufacturing including Vaccine development

Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals

  • Global Summit around the World – JP Morgan of the East as we were called – it is Now a Global Conference vs East Coast
  • Record number of Drugs approved as New Drugs with special quality
  • explosion of modality of therapies to include Gene Therapy
  • Billion underserved vs N-of-One drug
  • India’s President Modi allow healthcare access to 1/2Billion
  • collaboration across the World COVID Alliance in vaccine development
  • Global effort, China recovery is remarkable
  • India battle the infection and it is growing – Public Health
  • Remarkable Speakers
8-10 AM – 8-50 AM Panel Discussion- COVID-19: Where are we now? Where are we going?

Panelists:
Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health

  • Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred
  • Antibody testing
  • CRISPR test based
  • Vaccine in clinical trials, public need to return for 2nd shot, hesitancy
  • Who will get the Vaccine first? in the US  most vulnerable of those causing transmission
  • Pharma takes risk when efficacious level is unknown
    Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron
  • Repurpose – be careful
  • Ebola vaccine development approach is been REUSED for COVID-19
  • Existential threat by Disease – preparedness is ridiculous as size of investment – far where we need to be
  • Untreatable disease burden COVID-19 cost of healthcare calls massive increases as a society and Private sector Moderna invested in new technology from Academe to the Industry
  • Universal HealthCare will cripple the the healthcare systems
    Kiran Mazumdar-Shaw, Executive Chairperson, Biocon
  • Safety in proof of concept
  • Children focus for emergency use
  • validation of repurpose drugs
  • oral vaccine involve sequential processing, approval and TRUST,
  • concerns about risks
  • accelerate the process is the opportunity
    Dr. Rajeev Venkayya, President of the Global Vaccine Business Unit, Takeda
  • Public confidence in COVID-19 Vaccine
  • The Group with concerns at present is larger than 15 years ago due to the accelerate process od the development process
  • political influences on CDC emergency authorization given prior to election
  • hesitancy – influence of social media, conspiracies
  • Transparency by Pharma and by Regulatory Agencies
  • Independent reviews
    Dr. Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI)
  • 78 countries ready to participate, Healthcare workers priority to be ready end of next year

 

Moderator:
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School
8-50 AM – 8-55 AM Break + Polling
8-55 AM – 9-10 AM India Regulatory update

Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India

  • COVID related – support for Clinical Trials support to the Industry, innovators, processes and infrastructure is in place

Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization

  • partnership, time line, transparency
  • interaction online with regulators
  • 30 days approval pre and post approval – progress achieved
  • Online presubmission very useful to both sides
  • Ecosystems on early development: Gene therapy

Moderator:
Muna Bhanji, Senior Vice President,  Merck & Co.

  • India’s preparedness
9-10 AM – 9-15 AM Break + Polling
9-15 AM – 9-55 AM Fireside Chat

Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co.

Strategies of Merck = “Medicine is for the People not for Profit”

  • AntiViral – nucleocide – orally bioavailable
  • Vaccine in early development – BSV Vaccine used in EBOLA – attenuated virus vector platform experience – 1 single doze, deployed Globally
  • Vaccine modified Measles Vaccine, novel platform – out patient and Hospital
  • Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics
  • people will die from bacterial resistance infection and next pandemic will be bacterial not viral

Moderator:
Dr. Stelios Papadopoulos, Chairman of the Board, Biogen

  • Most important comments on urgency in investment in drug development by multiple constituencies made by
  • Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron
  • Access to therapy
9-55 AM – 10 AM Break + Polling
10 AM – 10-40 AM India Innovation Landscape

Panelists:
Amitabh Kant, Chief Executive Officer, National Institution for Transforming India (NITI)

  • Innovation in drug discovery collaboration for clinical trial infrastructure
  • BioEconomy BioSimilar the largest number approved anywhere
  • Incentives for size and scale
  • Ingredients manufacturing to become India’s priority
  • Investment in R&D and Human Capital in the BioEconomy

Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group

  • US history of innovations cluster and infrastructure: Academe, VC, small medium Biopharma, Government involvement
  • India: Contract research – 20 years history, lagging the ability to take risk
  • Changing, pricing of drug increased, innovating drug for local consumption, and it can be taken to US for a better price
  • Cancer immunology in India under development
  • India was Leading Chemistry Research – China’s government invested and took the market
  • Indian companies bigger in size – free on requirement imposed on China
  • India will be a great supplier to US Market to build high capacity raw materials

Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India

Resources are necessary 30% from Industry vs Government and Academe with great students and labs

Indian context – Personalized Medicine – Telemedicine and IT infrastructure allowing innovation in a 1Billion Population- sheer volume of quality professional

Dr. Naresh Trehan, Chairman, Medanta – the Medicity

  • Ecosystem ready for Government to promote innovations to conduct clinical trial with global acceptance standard
  • diverse gene pool in population to innovate for new molecule to market
  • Vaccine under development on Phase 1,2,3 – regulatory mechanism is in place
  • genetic drugs, BioSimilar dominance in the market – biotech can do clinical trials in India vs abroad

Moderator:
Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.

  • Largest producer of generic drugs
  • antiretroviral drug produced by Indian Pharma
  • Biotech innovations growing middle class – how innovation , infrastructure and shift to research
  • Diversify and become self reliance
10-40 AM – 10-45 AM Break + Polling
10-45 AM – 11-25 AM Panel Discussion- Oncology: Changing landscape- COVID learnings and the promise of new technologies

Panelists:
Dr. Alise Reicin, Former President, Global Clinical Development, Celgene

  • Clinical trial were impacted by association of patients to trials
  • anti bacterial resistance requires investment – needs will be greater for antibiotics in the future
  • Cancer mutation next therapy biomarkers for mutations to be developed

Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute

  • Dana Farber saw impact of COVID-19 on immunosuppressant population of patients coming in for Cancer Tx – switch from IV Tx to Oral
  • 96% decrease in screenings due to Pandemic – increase with Cancer diagnosis in coming years
  • No clinical Trials in Cancer were suspended – all continued
  • Telemedicine and working at home very efficient
  • Genomics of COVID-19 studies at Dana Farber same pathway identifies
  • safety and efficacy must be achieved – not to approve drugs without phase I & Phase II endpoints

Dr. Philip Larsen, Global Head of Research, Bayer AG

  • Repurposing drugs as antiviral from drug screening innovating methods
  • Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral  – dat of tested positive allows research of pathway in new ways
  • Regulatory agencies in US and Europe for types of drugs vs single patient drugs

Rehan Verjee, President, EMD Serono

  • entire volume of clinical trials at Roche went down same at EMD
  • delay of 6 month, some were to be initiated but was put on hold
  • Charities funding cancer research – were impacted and resources will come later and in decreased amount
  • New opportunities support access to Medicine
  • improve investment across the board
  • Antibody cytotoxic with precision

Dr. Tony Ho, Head of Research and Development, CRISPR Therapeutics

  • challenges overcome by testing at home

Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

  • New normal as a result of the pandemic role of personalized medicine
  • Cancer cure – what are the prospects
11-25 AM – 11-30 AM Break + Polling
11-30 AM – 12-10 PM Panel Discussion- Industry & Investment Outlook

Panelists:
Christopher Viehbacher, Managing Partner, Gurnet Point Capital

  • IPOs can have advantages in Pandemics – Travel curtails all deals done virtually in greater efficiency
  • Drug pricing is a target by White house
  • Dream of every Biotech – get Big Pharma coming to acquire and pay a lot
  • Morph and adapt

Daphne Zohar, Founder & CEO, PureTech Health

  • kill project early financial incentive not in line in the industry
  • incentive to move resources among project and kill early project experiments to find which project to kill
  • Innovations – pattern recognition, fast followers academic translation
  • Disease focus, best science is the decision factors

Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University

  • Digital Health
  • CVS opens clinics
  • R&D – Capital is low
  • Network of global innovation hubs vc investor channel like in the past
  • Value of company driven by hits blockbusters

 

Dr. Stelios Papadopoulos, Chairman, Biogen

  • Worst pandemic in our lifetime
  • stock market if hot – in balance in supply and demand, interest rates low, excess supply of equities in entertainment, Travel, hospitality
  • Healthcare was defensive therapeutics needed – opportunity to innovate in HC – shift money from entertainment, Travel hospitality to HC
  • Recovery will shift money away from Healthcare
  • IP Protection and patent expiration – biotech are cases not trends

Moderator:

Dr. Andrew Plump,

President of Research & Development, Takeda Pharmaceuticals

Moderator Presenter: Dr. Michael Rosenblatt, CEO
12-10 PM – 12-20 PM Break + Polling
12-20 PM – 1 PM Panel Discussion- Rare Diseases: No longer forgotten; but more to be achieved

ROI is not there, regulatory requirements reduced, Registry

Panelists:
Dr. Alfred Sandrock, Executive Vice President, Research & Development, Biogen

  • Multiple Sclerosis therapy
  • cost effectiveness is not there vs save a life
  • Appeal opportunity is there and regulators are people

Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda

  • Takeda collaborates with Grace Science Foundation

Dr. David Meeker, Chairman & CEO , Rhythm Pharmaceuticals

  • Cystic Fibrosis 

Dr. John Orloff, Head of Research & Development, Alexion

  • ALS
  • Duchenne Muscular Destrophy
  • HUS
  • ASO
  • gene therapy – one time therapy: Valuation for the industry of long term therapy: US (long term non existence) vs Europe and Japan (much appreciated

Matt Wilsey, Co-Founder & Chairman, Grace Science Foundation

  • Ultra-rare (500 Patients) vs Ultra Ultra-rare (50 Patients)
  • 70 patients in the World, Grace disease, Parent drive the search for drug
  • Manufacturing cost comes down
  • Price is dynamic

Moderator:
Dr. Steve Uden, Co-Founder, Rallybio

  • Regulators are people

 
1 PM – 1-05 PM Break + Polling
1-05 PM – 1-50 PM Fireside Chat

Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals

  • Congratulate Big Pharma for taking the challenge on COVID-19
  • Vaccine, Antibody and anti-viral
  • Government funding
  • Merck was independent from Government – to be independent and be able to set the price
  • HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there
  • Industry role: Competition of drug discovery capacity is been built, global needs, price need be low for global reach
  • Government is a already a player hoping without a control on pricing
  • 300Million people were treated FREE by Merck’s Family Program HepC
  • 9% in China immunize the newborn with HepB 1994 100% babies immunized – no profit to Merck – eradication of HepB in China
  • Neuro degeneration – science supports drug development
  • Role of R&D Scientists in Drug discovery?

Moderator:
Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson

  • COVID-19 drug development: Response by Big Pharma
  • Industry role in Access to medicines, biologics, antibodies, vaccines
  • Role of R&D Scientists in Drug discovery?
  • PAHTN – use Machine Learning on top of data collected routinely,

 
1-50 PM – 1-55 PM Break + Polling
1-55 PM – 2-35 PM Panel Discussion- Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World

Panelists:
Dr. Anne Heatherington, Head of Data Sciences Institute, Takeda Pharmaceuticals

  • Reliance on Data – AI and Data in Pharma alliance with MIT
  • collaboration of Data for COVID-19
  • Women need education in STEM and in Data Science

Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co.

  • Data on Patients and identification who will benefit fro which therapy
  •  cultural bias risk aversion
  • Invest early on in STEM

Dr. Maya Said, Chief Executive Officer, Outcomes4Me

  • Cancer patients taking change of their care
  • Digital Health – consumerization of Health, patient demand to be part of the decision, part of the information
  • FDA launched a Program Project Patient Voice

https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice

  • Women should not undersell themselves

Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson

  • Validation
  • Deployment of algorithms
  • embed data by type early on in the crisis to understand the disease
  • Compare the Big IT-Data and Pharma where are the barriers?
  • STEM and Women in Pharma – the opportunity must be right

Nina Kjellson, General Partner, Canaan

  • Data science is a winner in Healthcare
  • Women – Data Science is an excellent match

Moderator:
Sastry Chilukuri, President, Acorn AI- Medidata

  • Opportunities in Data Science in Pharma
  • COVID-19 and Data Science
  • STEM and Women in Pharma

 
2-35 PM – 2-40 PM Break + Polling
2-40 PM – 3-20 PM Panel Discussion- R&D Strategies and Trends: Innovation – The Big I

Panelists:
Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals

  • Enter for Plasma and for manufacturing vs discovery
  • Change how pharma behaved inefficiently in the past – with COVID-19 new behaviors in the industry
  • End of Century most diseases could be cured

Dr. David Reese, Executive Vice President, Research and Development, Amgen

  • Interaction with regulator was most favorable

Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline

  • Cytokine storm – few approaches
  • Control molecule GSK owned
  • GWAS not easy to find which gene drives the association
  • Functional Genomics gene by gene with phenotypes using machine learning significant help

Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson

  • Neuro-modulation: Symptomology Outcomes – no correlation
  • Vaccine platform used in the past for several vaccines: Selection process from several candidates, cell line enter Clinical waiting for data
  • Using same platform with several proteins – great communality in the development
  • Regulator deepen trust relationship which will carry for the future
  • Pulmonologists and cardiologist in the COVIS-19 Patients – remove drugs monitoring on drugs

Moderator:
Duval Patel presented the Moderator

Moderator:

Martin Mackay, Co-Founder, RallyBio

 
3-20 PM – 3-30 PM Closing Remarks

  • Every year it is getting better
  • India – innovate and make drugs for every country and for India
  • Diversity and inclusion
  • Leadership in Pharma Industry in all Panels
  • Massive impact can be made

 

Poll Questions for September 4

Polling Time (EST) Polling Topic
8-50 AM COVID-19 PanelQuestion 1: What do you foresee as the most likely outcome of the race to develop a vaccine?

  • Heightened international tensions due to inequities in distribution
  • Use of the vaccine as an instrument of geopolitics
  • Collaboration between governments to use vaccine to end the pandemic
  • All of the above

Question 2: What minimum criteria would you like to see for approval of COVID19 vaccines, assuming adequate efficacy?

  • Immune response in people over 60 years
  • Durability of response
  • Antibody plus T-cell response
  • Emergency Use Authorization with caveats followed by final approval
9-10 AM India Regulatory UpdateHow will MNCs respond to the recent regulatory changes for BioPharmas in India? They are _____ to run clinical trials there:

  • More likely
  • Less likely
  • Equally likely
9-55 AM Fireside Chat: Ken Frazier

The BioPharma industry this year has publicly committed itself to greater diversity. What specific measures do you expect to see?

  • Increasing diversity in clinical trials
  • Increasing diversity at the C-suite and board level
  • Increasing diversity throughout the company
  • All of the above
  • None of the above
10-40 AM India Innovation LandscapeWhat is the most important step India could take to become a global leader in life sciences innovation?”

  • Implement government policies to incentivize innovative drug development
  • Increase availability of financing for BioPharmas
  • Improve clinical trial infrastructure
  • Increase IP protection
11-25 AM Oncology PanelQuestion 1:

Changes in policy and reimbursement over the next five years will impact innovation in cancer therapeutics

  • Not at all
  • Slightly
  • Moderately
  • Significantly

Question 2: What therapeutic innovation do you think will have the biggest impact on cancer in the next five years?

  • Cell-based immunotherapies
  • Antibody-based immunotherapies
  • Bispecific / multi-specific antibodies
  • Antibody drug conjugates
12-10 PM Industry & Investment Outlook PanelMore and more funding has been going into preclinical companies — do you expect this trend to continue?

  • Yes
  • No

R&D Strategies and Trends Panel

COVID-19 has led to an unprecedented level of collaboration among stakeholders in the biopharma industry. Where do you expect to see the biggest increase in collaborations post-pandemic?

  • Discovery/preclinical research
  • Clinical development
  • Manufacturing
  • Commercialization
1 PM Rare Diseases PanelWhat is the biggest barrier to access to Orphan drugs in low-income countries?

  • Price, Access and Availability
  • Disease recognition and diagnosis
  • Lack of patient education regarding new therapies
  • Ultra-rarity of certain diseases creates barriers for BioPharma companies to pursue therapeutic
1-50 PM Fireside Chat: Roy VagelosQuestion 1:

Will pharma’s reputation continue its positive trend or return to negative base line beyond the pandemic

  • Yes
  • No

Question 2:

COVID-19 has put the spotlight on BioPharma as an essential player in the return to normalcy. What primary action do you think the industry needs to take to maintain a positive reputation beyond the pandemic?

  • Continue developing innovative drug pricing models
  • Increase drug pricing transparency
  • Increase data sharing and transparency
  • Improving availability and access in low income countries
2-35 PM Digital & Data Sciences PanelWhere has COVID-19 had the biggest impact on your adoption and use of digital health technologies?

  • Remote clinical trials and patient monitoring
  • Real-world data collection and analysis
  • Virtual drug launches

 

@@@@

In these unprecedented times due to COVID-19, USAIC is offering Free Registration for its annual summit.

Click for free registration

 

AGENDA & SPEAKERS

Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Summit Theme: “From N of One to N of a Billion”

  • Moderated Fireside Chat- Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. and Stelios Papadopoulos, Chairman of the Board, Biogen
  • Moderated Fireside Chat- Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals and Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Moderated Fireside Chat- K. VijayRaghavan, Principal Scientific Advisor, Government of India and Amitabh Kant, CEO, National Institution for Transforming India (NITI)

Panel Discussions:

  • Covid-19: Where are we now? Where are we going?
  • Oncology: A never ending tunnel?
  • Rare Diseases: Breaking Barriers for a Healthy Brain
  • Digital & Data Sciences: Leveraging data and digital to achieve healthcare solutions
  • Industry & Investment Outlook
  • R&D Strategies and Trends: Innovation – The Big I

Program and speakers subject to change*

14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Speakers

Kenneth Frazier
Chairman of the Board & CEO
Merck & Co.
Dr. Andrew Plump
President of R&D
Takeda Pharmaceuticals
Dr. Laurie Glimcher
President & CEO
Dana-Farber Cancer Institute
Dr. Roy Vagelos
Chairman of the Board
Regeneron
Dr. Stelios Papadopoulos
Chairman of the Board
Biogen

Christopher Viehbacher
Managing Partner
Gurnet Point Capital
Dr. Mathai Mammen
Global Head of R&D
Janssen- Johnson & Johnson
Kiran Mazumdar Shaw
Chairperson & Managing Director
Biocon
Dr. Hal Barron
President, R&D and CSO
GlaxoSmithKline
Prof. K. Vijay Raghavan
Principal Scientific Advisor
Government of India

Dr. George Yancopoulos
Co-Founder, President & CSO
Regeneron
Dr. Elias Zerhouni
Professor Emeritus
Johns Hopkins University
Daphne Zohar
Founder & CEO
PureTech Health
Sanat Chattopadhyay
President- Merck Manufacturing Division
Merck & Co.
Dr. David Reese
Executive Vice President- R&D
Amgen

Hari Bhartia
Founder & Co-Chairman
Jubilant Bhartia Group
Dr. Alfred Sandrock
Exe Vice President R&D & CMO
Biogen
Dr. Najat Khan
Chief Operating Officer, Data Sciences
Janssen- Johnson & Johnson
Dr. Richard Hatchett
Chief Executive Officer
CEPI
Amitabh Kant
Chief Executive Officer
NITI Aayog

Dr. Martin Mackay
Co-Founder
Rallybio
Dr. Daniel Curran
Head of the Rare Diseases TA
Takeda Pharmaceuticals
Dr. Alise Reicin
Former President, Global Clinical Dev.
Celgene
Dr. David Meeker
Chairman & CEO
Rhythm Pharmaceuticals
Dr. John Orloff
EVP and Head of R&D
Alexion

Dr. Barry Bloom
Professor & former Dean
Harvard School of Public Health
Dr. Mandeep Bhandari
Joint Secretary
Ministry of Health, India
Arpa Garay
President, Commercial Analytics
Merck & Co.
Dr. Steve Uden
Co-Founder
Rallybio
Dr. Philip Larsen
Global Head of Research
Bayer AG

Sastry Chilukuri
Executive Vice President
Medidata
Dr. William Chin
Professor of Medicine, Emeritus
Harvard Medical School
Dr. Anne Heatherington
Head of Data Sciences Institute
Takeda Pharmaceuticals
Dr. V G Somani
Drugs Controller General of India
Government of India
Dr. Rajeev Venkayya
President-Global Vaccines
Takeda

Dr. Raju Kucherlapati
Professor of Genetics
Harvard Medical School
Matt Wilsey
Co-Founder & Chairman
Grace Science Foundation
Muna Bhanji
SVP, Global Market Access
Merck & Co.
Dr. Maya Said
Chief Executive Officer
Outcomes4Me
Rehan Verjee
President
EMD Serono
Pharmasia News Biospectrum India Online

SOURCE:

https://usaindiachamber.org/speaker.php

Read Full Post »

Life Science and Digital Health Investments – 2020 World Medical Innovation Forum – COVID-19, AI – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Posted in AI-assisted Cardiac MRI, Artificial intelligence applications for cardiology, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Artificial Intelligence in Psychiatry, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Coronavirus Gene Expression, COVID-19, Deep Learning in Pathology, Innovations, Population Health Management, Genetics & Pharmaceutical, R&D Expenditure, SARS-CoV-2, Serology tests for coronavirus antibodies, Virus Infective Acute Respiratory Syndrome: SARS-CoV on May 12, 2020| Leave a Comment »


2020 World Medical Innovation Forum – COVID-19, AI  – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

 

 

 

Life science and digital health investments have continued at a strong pace during the COVID-19 crisis. Senior investment leaders discuss what to expect. Will:

  • social distancing affect deal making?
  • key asset categories remain strong – venture, private equity, public offerings, acquisitions?
  • valuations hold up in some categories while others fall?

Moderator: Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham


Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures, Chair NVCA

Phillip Gross, Managing Director, Adage Capital Management

Christopher Viehbacher, Managing Partner, Gurnet Point Capital

 

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Posted in BioSimilars, BioTechnology - Venture Creation, Breast Cancer - impalpable breast lesions, Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, Cancer-Immune Interactions, CAR-T, Circulating Tumor Cells (CTC), combination immunotherapies., Conference Coverage with Social Media, Drug Development Process, drug repurposing, Immuno-Oncology & Genomics, Immunotherapy, interventional oncology, Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Modulating Macrophages in Cancer Immunotherapy, Oncolytic virus & OncoViro-Therapy, Pharmaceutical Analytics, Pharmaceutical Discovery, Precision Cancer Medicine, Prostate Cancer: Monitoring vs Treatment, Scientific & Biotech Conferences: Press Coverage, tagged , , , , , , , , , , , on April 28, 2020| Leave a Comment »


Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Reporter: Stephen J. Williams, PhD

New Drugs on the Horizon: Part 3
Introduction

Andrew J. Phillips, C4 Therapeutics

  • symposium brought by AACR CICR and had about 30 proposals for talks and chose three talks
  • unfortunately the networking event is not possible but hope to see you soon in good health

ABBV-184: A novel survivin specific T cell receptor/CD3 bispecific therapeutic that targets both solid tumor and hematological malignancies

Edward B Reilly
AbbVie Inc. @abbvie

  • T-cell receptors (TCR) can recognize the intracellular targets whereas antibodies only recognize the 25% of potential extracellular targets
  • survivin is expressed in multiple cancers and correlates with poor survival and prognosis
  • CD3 bispecific TCR to survivn (Ab to CD3 on T- cells and TCR to survivin on cancer cells presented in MHC Class A3)
  • ABBV184  effective in vivo in lung cancer models as single agent;
  • in humanized mouse tumor models CD3/survivin bispecific can recruit T cells into solid tumors; multiple immune cells CD4 and CD8 positive T cells were found to infiltrate into tumor
  • therapeutic window as measured by cytokine release assays in tumor vs. normal cells very wide (>25 fold)
  • ABBV184 does not bind platelets and has good in vivo safety profile
  • First- in human dose determination trial: used in vitro cancer cell assays to determine 1st human dose
  • looking at AML and lung cancer indications
  • phase 1 trial is underway for safety and efficacy and determine phase 2 dose
  • survivin has very few mutations so they are not worried about a changing epitope of their target TCR peptide of choice

The discovery of TNO155: A first in class SHP2 inhibitor

Matthew J. LaMarche
Novartis @Novartis

  • SHP2 is an intracellular phosphatase that is upstream of MEK ERK pathway; has an SH2 domain and PTP domain
  • knockdown of SHP2 inhibits tumor growth and colony formation in soft agar
  • 55 TKIs there are very little phosphatase inhibitors; difficult to target the active catalytic site; inhibitors can be oxidized at the active site; so they tried to target the two domains and developed an allosteric inhibitor at binding site where three domains come together and stabilize it
  • they produced a number of chemical scaffolds that would bind and stabilize this allosteric site
  • block the redox reaction by blocking the cysteine in the binding site
  • lead compound had phototoxicity; used SAR analysis to improve affinity and reduce phototox effects
  • was very difficult to balance efficacy, binding properties, and tox by adjusting stuctures
  • TNO155 is their lead into trials
  • SHP2 expressed in T cells and they find good combo with I/O with uptick of CD8 cells
  • TNO155 is very selective no SHP1 inhibition; SHP2 can autoinhibit itself when three domains come together and stabilize; no cross reactivity with other phosphatases
  • they screened 1.5 million compounds and got low hit rate so that is why they needed to chemically engineer and improve on the classes they found as near hits

Closing Remarks

 

Xiaojing Wang
Genentech, Inc. @genentech

Follow on Twitter at:

@pharma_BI

@AACR

@CureCancerNow

@pharmanews

@BiotechWorld

@HopkinsMedicine

#AACR20

Read Full Post »

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Posted in BioTechnology - Venture Creation, IP Development by LPBI Group Team, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on February 28, 2020| Leave a Comment »


Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Author: Aviva Lev-Ari, PhD, RN

https://feinternational.com/blog/how-do-you-value-an-online-business/

How to Value a Website or Internet Business in 2020

 

From: Thomas Smale <acquisitions@feinternational.com>

Reply-To: <acquisitions@feinternational.com>

Date: Thursday, February 27, 2020 at 4:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Your Guide to Buying an Online Business

Hi Aviva

Thanks for your interest in our free Guide to Buying an Online Business. Please click below to download.

Guide-to-Buying-an-Online-Business-vLQ

Guide-to-Buying-an-Online-Business-vHQ

We will be in touch in a few days to see if you have any questions!

Regards,


Thomas Smale
Founder

FE International, Inc.

www.feinternational.com

Follow us on Facebook, LinkedIn and Twitter.

 

FE International Framework

Alternative Metrics for Valuing Websites Or Internet Business

  • Discounted Cashflow Analysis
  • Precedent Transactions
  • Earnings-Multiple
  • Traffic Valuation
  • A Multiple-Based Approach to Valuing a Website or Internet Business

Defining Profitability

Factors That Influence The Multiple: Financials, Traffic, Operations, niche, Customer base

Valuation Multiples In Practice

Image source:

https://feinternational.com/blog/how-do-you-value-an-online-business/

Consider the Current Business Model

How to Value a SaaS Business

How to Value an E-Commerce Business

How to Value an App

 

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

On 2/27/2020 5:30AM – Aviva Wrote:

This is an excellent article.

It is very applicable for

1. Travel Websites

2. eCommerce transaction sites

3. Content: chiefly NEWS

CLAIMER:

Our PharmaceuticalIntellugence.com

A. Is an Internet based Business of Digital Content

B. Unlike 1,2,3 – 

B.1 EVERY CURATION in the Journal

has content with INTRINSIC value in the form of IP belonging to the Curator’s Expertise

B.2 ALL 16 Volumes in the BioMed e-Series represent an ORIGINAL electronic Table of Contents eTOCs designed by a very unique Editor(s).

B.2.1 The evolution of the eTOCs takes many iterations among the editors AND only the Editor-in-Chief after requests for substantial alterations, usually ADD new content, declares “This is the final eTOCs for Series X, Volume Y.

(These alterations AUGMENT the IP embedded in the eTOCs design)

Example: 

Genomics Volume 2: there were three iterations of eTOCs between Prof. Feldman and Aviva, first dated 2016. 

In 2019, 

• Aviva created single handedly the FINAL version of eTOCs and 

• commissioned ALL scientists to populated Parts 7 and 8 with new content not in existence in the Journal. 

• made Part 3: AI in Medicine

• made Part 4: Single Cell Sequencing

• obtained from Part 5: Evolution & Genomics from Prof. Feldman as an original curations WRITTEN for this Volume 

THAT IS INTRINSIC VALUE DERIVED FROM EXPERTISE and it defines the QUALITY of this book, which is not measured by traffic. Advertisement of the book could drive page downloads and book sales. It can be done ANY TIME because each article in the book is updated in perpetuity !! A feature of our BioMed e-Series.

Does the DCF model capture the value of NON-perishable content in our Jornal and Books – no it does not

It will be valued at PREMIUM an acquirer who is sensitive to content obsolescence !!!!!

B.2.2 Page downloading will be updated for 4/19/2020

C. eProceedings are generated by Experts and the TWEET Collections carry the favorable Tweet Analytics that we presented: 

• HIGH engagement, 

• HIGHEST ratio tweet/likes in the Industry

• Ranked 2nd, 3rd, 4th in TOP 10 Influencers at #1 Conference in AI in Medicine in the World, 4/2019

HOW THUS VALUATION article calling for 2 to 4.5 multiplier is to capture LPBI’s

1. ECONOMIC intrinsic value on non perishable content 

2. Top Expertise

3. electronic Reputation and other INTANGIBLE ASSETS as VALUE DRIVERS

FE International’s model has only LIMITED applicability to valuation of LPBI Portfolio of Intellectual Property.

Our venture shares several industries, we have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house to mitigate the information explosion in the Life Sciences and the information obsolescence. The content lands its attribution to electronic Scientific Publishing and to Pharmaceutical Media. Please review the business functions that this content could contribute to by the value drivers in each economic segment https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

http://pharmaceuticalintelligence.com

  •  LPBI Scientific Journal: 1.7Million eReaders, 5700 scientific articles [Pharmaceutics, Life Sciences, Medicine], 690 categories of research, 10,154Tags

https://lnkd.in/eEw5q7N

  • BioMed e-Series: 16 Volumes in Medicine and Life Sciences

https://lnkd.in/ekWGNqA

  •  e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference.

https://lnkd.in/dc2qGAK

OTHER ASSETS

  • Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
  • Asset Class V is a Gallery of ~5000 images used in the articles and books
  • Asset Class VI is the Team of Experts.
  • Asset Class VII: Royalties on BioMed e-Series

Read Full Post »

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

Posted in BioTechnology - Venture Creation, Conference Coverage with Social Media on February 21, 2020| Leave a Comment »


2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in REAL TIME

for

http://pharmaceuticalintelligence.com

by

@pharma_BI @AVIVA1950 @MassBio

https://events.bizzabo.com/231443

Speakers

https://massbio.microsoftcrmportals.com/speakers/?event=2020_State_of_Possible_Conference378018264

Agenda Tracks

https://massbio.microsoftcrmportals.com/event/tracks/?event=2020_State_of_Possible_Conference378018264

Live Stream

https://massbio.microsoftcrmportals.com/event/livestream/?event=2020_State_of_Possible_Conference378018264

Wed Aug 26

Wed Aug 26
9:30 AM
Networking
10:00 AM
Main Stage: Welcome & Changing the Narrative Panel
Mike Nikitas
Master of Ceremonies
Moderator
  • How the message form Patient is to be shared to get the impact deserved
  • How do we tell the stories
  • 1/2 or 1/3 would get the Vaccine if it is available NOW
Robert Coughlin
President and Chief Executive Officer
  • David Lucchino – CEO Frequency Therapeutics Mentor to Robert Coughlin – had two years of record success
MassBio
Speaker
David Lucchino
MassBio’s Immediate Past Board Chair and Co-founder, President and Chief Executive Officer
Frequency Therapeutics
  • Cancer survival [Millenium & Takeda drug prolonging life for Multiple Myeloma], Therapeutics developer, CEO in Biotech and President and Chief Executive Officer, MassBio
  • High performance students from suburban school were recruited to get opportunities in biotech
Speaker
Charles Wilson
MassBio’s Board Chair and President and Chief Executive Officer
Unum Therapeutics
  • Incoming MassBio’s Board Chair and President
  • Sustainability and opportunities
  • Fight COVID-19, develop Vaccines
  • Infrastructure to increase productivity
  • Equity, diversity inclusion in Biotech
Speaker
  • Math needed to be done for drugs selling
  • Front line to bring drugs – Price too high – explain
  • comorbidity continues during the Pandemic – two stories need now efforts
  • Story: What is memorable and relatable
  • Leadership needs to share the stories of themselves vs talking about Financial
  • Talk about failing
  • Be careful with Vaccine to be presented as an industry issue
  • Strong supporter to encourge volunteers to get the Vaccine
  • The industry needs Solutions not winners
11:15 AM
Networking
11:30 AM
Business Breakout: Resilience, Grit, Freedom to Fail…and Pivot
Stuart Peltz
Founder and Chief Executive Officer
PTC Therapeutics, Inc.
Moderator
Barbara Fox
Chief Executive Officer
Rheos Medicines, Inc.
Panelist
Anna Protopapas
President & Chief Executive Officer
Mersana Therapeutics, Inc.
Panelist
Science Breakout: Lifting the Curtain on R&D to Advance New Drugs Faster
Adam Feuerstein
Senior Writer, Biotech
STAT
Moderator
Katie Ellias
Managing Director
JDRF, T1D Fund = Not-for profit on Diabetes T1D
  • Foundation works during the years to identify who is at risk
  • New avenues of Science – in development of therapies
  • Data sharing, Outreach to Academia
  • Meetings organized as an Educational day under CDA Pharma and the Foundation – Target of Exploration
  • What is the Foundation interested in and Pharma collaboration
  • Transparent with the Foundation due to under CDA
  • Beta cell Stress vs Stress Companies – targeting Tissue by other companies for other indication – co-develop a plan
  • accelerate projects to invest in therapeutics then other investors pick up
  • Immune response is an area of interest – Disease specific educate regulators on candidates
  • Manufactoring changes for COVID-19
Panelist
John Tallarico
Head, Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
Novartis
Panelist
  • Gilead, Takeda and Novaris – Working together on Coronavirus on R&D aspects
  • Create a Journal of Negative Results – share what was tried but did not work
  • proprietary targets are under greatest secrecy at Novartis
  • Novartis Global Scholar Program – Select Academic Institutions for Tech Licensing
  • Collated from across all parts of Novaris – THIS IS THE PLAY BOOK for the Future and Academis Instituions share with they researches and they submit Intent to collaborate
  • Can the collaboration for COVID-19 can be ported to OTHER areas of research – attempts will be done because it is rewarding
  • COVID-19 helped transfer reagents across organization beyond COVID-19 – Silos will remain due to IP channels requiring strict protection
  • What emerged with OCVID-19 will be preserved vs adandoned like after SAR in 2004
12:00 PM
Facilitated Networking: Lifting the Curtain on R&D to Advance New Drugs Faster Breakout
BROADCAST

Starts 2 min before the session time

Facilitated Networking: Resilience, Grit, Freedom to Fail…and Pivot Breakout Session
BROADCAST

Starts 2 min before the session time

12:15 PM
Main Stage: Henri A. Termeer Innovative Leadership Award Presentation
Robert Coughlin
President and Chief Executive Officer
MassBio
Abbie Celniker
Partner
Third Rock Ventures
12:25 PM
  • Opportunity to innovate
  • Innovation in Making Therapies
  • Ex-Genentech –>> Millenium –> Takeda
  • Mounting the Antibodies response by drugs
  • 1994 in Boston at GI – Genetic Institute – Hemophilia drugs developed – prophylactic treatment
  • 2007 Rock Ventures to see investment in Therapeutics – building teams with diversity is the challenge – expend the landscape to diverse background
  • Henri A. Termeer created access to diverse work force
  • This Award calls for taking risks
Networking
12:45 PM
Main Stage: Possible Talk: Patient Stories – Lina Rebeiz’s Road to Medical School
  • Diagnosis of Acute Intermittent Porphyria (AIP) – is a rare metabolic disorder that is characterized by partial deficiency of the enzyme hydroxymethylbilane synthase (also known as porphobilinogen deaminase). This enzyme deficiency can result in the accumulation of porphyrin precursors in the body.
Lina Rebeiz
First Year Medical Student
1:00 PM
Business Breakout: From Seed to Series A – Creative Ways to Fun Your Startup
Deborah Palestrant
Partner
5AM Ventures
Moderator
Raymond J. Tesi
President and Chief Executive Officer
ImmuneBio
Panelist
Stephen Kennedy Smith
Principal
Park Agency – Kennedy Enterprises
Panelist
Science Breakout: Realities of Precision Medicine – How Small is Too Small?
Jennifer Carter
Healthcare Executive, Board member and Entrepreneur
JLC Precision Health Strategies, LLC
Moderator
  • Rare diseases are different than Cancer – is the kinase different
  • There are rare cancers
  • How small is too small
Timothy Yu
Assistant Professor in Pediatrics
Harvard Medical School
Panelist
  • Neurologist in Genetics department of Children’s Hospital
  • Rare genetic disorders without Cancer
  • Genetically subcategorize patients like doing so in a pediatric disease sub-population
  • A drug was developed for ONE single patient
  • Nucleotide drugs allow using one platform for several genetics disorders: Same chemical class arranged differently suite of drugs the PK and PD is similar – common approach to treat different patients with same disease but in need for drugs that as slightly different in molecular arrangement
  • Same drug for multiple indications vs One disease with multiple specific drugs – multiple agents in ONE drug
  • the only way to make progress in rare disease
  • EGFR a case for Genetic disease treated by drugs dealing with the genetic disorder
  • Duchenne is another example EXON 51 vs CRISPR
  • N-of-1 is the standard achievable if Regulatory will join

 

Marion Dorsch
Chief Scientific Officer
Blueprint Medicines
Panelist
  • Rare disease drug — GI 500 patients – FDA allows approval & use after Phase 1
  • Pediatric population vs Adult
  • Target the genetic driver
  • Few hundreds is the current goal
1:30 PM
Facilitated Networking: From Seed to Series A – Creative Ways to Fun Your Startup
BROADCAST

Starts 2 min before the session time

Facilitated Networking: Realities of Precision Medicine – How Small is Too Small?
BROADCAST

Starts 2 min before the session time

1:45 PM
Main Stage: Possible Talk: Steve Burton, Determination Through Adversity
Steve Burton
Sports Anchor and Reporter
WBZ-TV
Speaker

Thu Aug 27

Thu Aug 27
9:30 AM
Networking
10:00 AM
Main Stage: Possible Talk: Empowering the Financial Lives of People & Companies with Morgan Stanley
  • David Lacchino – is praised by MassBio and Executive Team
  • Encourage diversity, risk taking, affects people and management
  • as cancer survivor did inspired Frequency Therapeutics
  • Thanking him for high Bar, impacting patients around the Globe
Jed Finn
Head of Corporate and Institutional Solutions; COO, Wealth Management
Morgan Stanley
Speaker
10:15 AM
  • Morgan Stanley (MS) – growth faster of peers $50Trillion Asset in Management +$1MM age +50 years old – Emerging segment – moving from Branch to online – direct to client – did not yet developed
  • In the institutional space – Siliant was acquired a SW cloud-based Canadian for combined Employers and Employees
  • Education, Retirement Readiness  and Wealth Management for Employees via endorsement from Employers
  • MS offers services to biotech

MS @ works

  • Benefits for Employers: The C-Suite AND all other employees, lowest fees, Portal soon to be released – How many of the Employees are selleing are holding are buying, shares hold by Employees
  • Benefits for Employees – Individual Holdings, account reviews and Consulting offered to Employees, Financial Wellness Program to be provided by the Employer is desired by Employees
Business Breakout: Supporting Regional Growth of the Life Sciences Beyond Cambridge
Mathias Cousin
Managing Director
Deloitte
Moderator
Jim Glasheen
Executive Vice Chancellor
University of Massachusetts Medical School
Panelist
Matt Daniels
Executive Managing Director
JLL
Panelist

Science Breakout: AI and Drug Discovery: Marrying Data Science with Core Biology

Colin Hill
Chief Executive Officer, President, Chairman, and Co-Founder
GNS Healthcare
Moderator
  • cellular phynotype, drug target and therapeutics outcome
  • data is most important technology and Biology which has many interpretations done by different biologists
  • computer models need one interpretation vs many: Yes no rule bases are needed
Juan Alvarez
AVP, Computational and Structural Chemistry
Merck & Co., Inc.
Panelist
  • Drug Target identification
  • Drug Discovery – ML since 1980s
  • Identify molecules
  • syntesis prediction
  • physico space – physiological systems – Transcriptomics, single cell biomarkers, proteomic, metabolomics
  • evolving proteins
  • analyzing data
  • access to compute power data acquisition and storage – High dimensional spaces sample comparison
  • Find therapies for Humans in the absence of having Humans participating, data on human is BIASED by drugs history
  • Drugable – identify interventions translatable to Humans pathway-based
  • Pessimist: Unknowns and changes are inevitable
  • COVID-19 – some problems can be solved, some are changing environment
  • collect specimens from melanoma easier than from others
Renée Deehan-Kenney
PhD, VP, QuartzBio
Precision Medicine Group
Panelist
  • technology enable company clinical data analysis of data clical trials
  • ML prior knowledge
  • network biology
  • drive inside
  • MOA prioritize indications
  • Chemistry in developing drugs is complex
  • Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line
  • Pessimistic view: Long way to go end point most of the time are not good, not in my life time
  • must try encoouraged by published data
  • love basic research not in Academe
10:45 AM
11:00 AM
Main Stage: Possible Talk: The Process of Turning What Ifs into Realities through the Life Sciences & State of Possible Award Presentation
Judy Luu
Student
UMass Amherst
Speaker
Robert Coughlin
President and Chief Executive Officer
MassBio
Speaker
Kenneth Anderson
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Speaker
  • Multiple Myeloma – 23 drugs approved by FDA
  • Dana-Farber Cancer Institute with Sanofi collaboration
  • Foundations stepped forward to study Multiple Myeloma
  • FDA motivated to help patients Hematologic Division – African Americans
  • Change paradigm of clinical trials
  • Geraldine Feraro was a patient at DFCI
  • Tom Bracow was a patient at DFCI
  • Ronald Burden – sports
  • STEM – girls 6th grade to 12 grade
  • David Lacchino – patient at DFCI
Joe Malarney
Complex Manager and Managing Director
Morgan Stanley
Speaker
11:30 AM
Networking
12:00 PM
Main Stage: Building a Digital Health Community in Massachusetts and Keynote
Speakers
Naomi Fried
Founder and Chief Executive Officer
Health Innovation Strategies
Moderator
  • MA best Hospitals: MGH-BWH, Beth Israel-Lahey Clinic, Stuart
  • BC/BS
  • Medical Schools
  • Clusters in Biotech & Digital Health Counsel
  • Definition of Community changed in the COVID-19 Era
  • connected is having a new meaning
  • Service providers will play in building DIGITAL Communities
Stephen Bernstein
Attorney at Law
McDermott Will & Emery LLP
Panelist
  • Webinars and Zooms allows communication – we will see more innovations – Flatten the World
  • Greater isolation – US is expected to lead
  • collaborate is NOW home based – no travel – be creative
  • Virtual Clinical Trials
  • Virtual Bench science
  • Life sciences Products; Deploying a compound, provider responsible for the cost or how the Reimbursement will work
  • Consumer & Patients: Specialty Pharmacy
  • collaborations by planning ahead
  • Virtual will be inevitable if more social distancing will take place
Nick Dougherty
Managing Director
MassChallenge HealthTech
Panelist
  • Around the World communities, MA Biotech infrastructure
  • MassChallenge HealthTech: In Mexico, in Israel in Switzerland
  • Becoming virtual instantly in MARCH 2020
  • More locations pick up and scale up innovations around the Globe
  • Financial constraints, solve old problems
Thomas McCourt
President
Ironwood Pharmaceuticals, Inc.
Panelist
  • GI disease in Patients – My Gi Health started in NIH – symptoms of GI diseases
  • GI entrepreneurs to build a smart e-Tool to analyze the GI Symptoms
  • few thousand Patients
  • Clinical trials many are STUCK – solve problems calls for adoption of all companies to digital platforms
  • Entrepreneurial spirit in Kendall square took away the prime position of CA Biotech
Main Stage: Keynote: Leading in 21st Century Technologies: Our Products and Our People and Closing Remarks
BROADCAST

Starts 2 min before the session time

Susan Hockfield
President Emerita
Massachusetts Institute of Technology
Keynote
  • Regional advantage: Collaborations among industry and academia.
  • Biotech – emerging technologies cusp: Biology convergence with Engineering: sweetspot
  • resources to be used more productively: Opportunities to include supremely talented people
  • MA lead by people, by products : Digital Technologies: Physics & Engineering 1.0 to build devices: Electronics industry
  • 21st Century: Partless Biology – DNA, RNA: Biology and Engineering 2.0  Pathways, water,
  • 2.0 Technologies for Diagnostics for COVID-19: is frustrating
  • Healthcare Cost: Diagnostics too late and too expensively treated
  • Convergence technology in Cancer: Diagnosis is still two late: Synthetic Biomarkers: Disease specifics enzymes in nano particles used in diagnosis of cancer cells – urine based Test for cancer
  • Inhaling of particles Volatile organic nano particles can be exhaled for the diagnosis
  • Future Founders Initiative: Data, Approaches, Implementation
  • MIT Faculty founding of companies: 56 companies only 2 founded by Women: Inclusion of Women and Black impact GDP and innovations
  • Bootcamp for Women from the Lab to the Market place
  • Funding start ups: For Women founded and more women on boards increased to 25% signed by VC Association to track
  • Draw on more of our TALENTED people as advantages to be drown in the action to invent a better future
Mike Nikitas
Master of Ceremonies
Speaker
Robert Coughlin
President and Chief Executive Officer
MassBio
Speaker

Read Full Post »

Older Posts »